ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0430

Retrospective evaluation of the clinical impact of democgraphic , serological , clinical , radiological parameters and treatment modalities in patients with RA-ILD

fatih ŞAhiner1, Mine Nokay2, funda erbasan2, Veli Yazisiz3 and Ender terzioglu2, 1Akdeniz University, Antalya, 2Akdeniz University, Antalya, Turkey, 3Akdeniz University, Faculty of Medicine, Antalya, Turkey

Meeting: ACR Convergence 2025

Keywords: Anti-CCP, interstitial lung disease, rheumatoid arthritis, Rheumatoid Factor

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0430–0469) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: RA-ILD is significant determinants of morbidity and mortality. This study aims to evaluate the demographic and serological characteristics of RA-ILD patients and investigate the relationship with smoking, phenotypic features and lung involvement using HRCT, treatments administered, and parameters affecting mortality.

Methods: We evaluated 65 patients with RA-ILD who showed interstitial changes on HRCT imaging. We collected data on demographics, clinical findings, laboratory results, pulmonary function tests, HRCT images, and treatments from the hospital information system patient records. We analyzed the relationships between disease progression, mortality, and factors such as age, gender, smoking history, serological test results, disease duration, HRCT findings, DAS28-ESR, pulmonary function tests, and treatments.

Results: The study included 65 patients, with a mean age of 67.14 ± 9.52 years. 60% were female and 40% were male. Of the total, 26.2% had died, with 58.8% of these deaths attributed to ILD. Patients who had lung involvement exceeding 20% on HRCT had a significantly higher mortality rate. Serological evaluations showed high positivity rates for RF at 60% and ACPA at 71.4%. The mean duration between diagnoses of RA and ILD was 7.82 ± 10.16 years. The most common HRCT pattern observed was UIP, present in 46.2% of patients, while 32.3% had lung involvement exceeding 20% on HRCT. At the time of ILD diagnosis, 33.3% of patients were in remission, which increased to 71.9% at the final follow-up. The proportion of patients exhibiting high disease activity decreased from 3.5% initially to none at the last evaluation. Additionally, FVC and diffusing capacity of the lungs for DLCO values declined over time, with the final mean DLCO value recorded at 56.69 ± 21.68. In terms of treatment, 90.8% of patients received MTX, 75.4% received HCQ, and 56.9% received RTX.

Conclusion: Our study findings indicating that RA-ILD is more common in older patients, males, seropositive individuals, and with a smoking history. RA-ILD mortality is higher than non-ILD. Among ILD phenotypes, UIP is the most frequently observed pattern, with higher lung involvement percentages in this group. As lung involvement increases, pulmonary function declines, and mortality rises. Consistent with previous studies, no correlation was found between seropositivity, DAS28 score, and ILD phenotype. However, although numerically significant, the finding that patients with high-titer seropositivity may have more extensive lung disease was not statistically significant. In deceased patients, pulmonary function test results were lower, disease activity was higher, and the interval between RA and ILD diagnoses was shorter. Patients with high disease activity at RA diagnosis had lower FVC values at ILD diagnosis, while those in remission had higher FVC values. Patients with UIP and NSIP patterns exhibited greater declines in pulmonary function, with UIP associated with higher mortality. Unlike similar studies, no significant decline in FVC and DLCO values was observed with increased smoking history. Furthermore, in contrast to previous research, no statistically significant relationship was found between TNFi agents and mortality.

Supporting image 1Table 1. Age and Gender Characteristics

Supporting image 2Table 2. FVC and DLCO values at diagnosis and last follow-up According to ACPA positivity

Supporting image 3Table 3. HRCT Pattern and Involvement Rate According to RF Positivity


Disclosures: f. ŞAhiner: None; M. Nokay: None; f. erbasan: None; V. Yazisiz: None; E. terzioglu: None.

To cite this abstract in AMA style:

ŞAhiner f, Nokay M, erbasan f, Yazisiz V, terzioglu E. Retrospective evaluation of the clinical impact of democgraphic , serological , clinical , radiological parameters and treatment modalities in patients with RA-ILD [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/retrospective-evaluation-of-the-clinical-impact-of-democgraphic-serological-clinical-radiological-parameters-and-treatment-modalities-in-patients-with-ra-ild/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/retrospective-evaluation-of-the-clinical-impact-of-democgraphic-serological-clinical-radiological-parameters-and-treatment-modalities-in-patients-with-ra-ild/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology